MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation
TSX:MDP • CA58410Q2036
Current stock price
3.94 CAD
+0.07 (+1.81%)
Last:
This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDP.CA Profitability Analysis
1.1 Basic Checks
- In the past year MDP has reported negative net income.
- In the past year MDP had a positive cash flow from operations.
- In multiple years MDP reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of MDP (-0.18%) is better than 71.88% of its industry peers.
- MDP's Return On Equity of -0.52% is fine compared to the rest of the industry. MDP outperforms 75.00% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 3.02%, MDP is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 8.03%.
- The last Return On Invested Capital (3.02%) for MDP is well below the 3 year average (9.89%), which needs to be investigated, but indicates that MDP had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROIC | 3.02% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- Looking at the Operating Margin, with a value of 3.91%, MDP is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
- The Gross Margin of MDP (53.87%) is better than 81.25% of its industry peers.
- In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. MDP.CA Health Analysis
2.1 Basic Checks
- MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- MDP has more shares outstanding than it did 1 year ago.
- MDP has more shares outstanding than it did 5 years ago.
- MDP has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.76, we must say that MDP is in the distress zone and has some risk of bankruptcy.
- MDP's Altman-Z score of 0.76 is in line compared to the rest of the industry. MDP outperforms 59.38% of its industry peers.
- The Debt to FCF ratio of MDP is 1.48, which is an excellent value as it means it would take MDP, only 1.48 years of fcf income to pay off all of its debts.
- MDP has a better Debt to FCF ratio (1.48) than 90.63% of its industry peers.
- MDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.35, MDP perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 0.76 |
ROIC/WACC0.34
WACC8.77%
2.3 Liquidity
- MDP has a Current Ratio of 1.12. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.12, MDP is not doing good in the industry: 78.13% of the companies in the same industry are doing better.
- A Quick Ratio of 0.62 indicates that MDP may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.62, MDP is doing worse than 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 |
3. MDP.CA Growth Analysis
3.1 Past
- MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.14%.
- The Revenue has decreased by -9.23% in the past year.
- The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
3.2 Future
- The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
- MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.80% yearly.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MDP.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 8.82, the valuation of MDP can be described as reasonable.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 84.38% of the companies listed in the same industry.
- MDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.82 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a somewhat cheap valuation: MDP is cheaper than 75.00% of the companies listed in the same industry.
- 87.50% of the companies in the same industry are more expensive than MDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.37 | ||
| EV/EBITDA | 7.53 |
4.3 Compensation for Growth
- MDP's earnings are expected to grow with 109.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%
5. MDP.CA Dividend Analysis
5.1 Amount
- MDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDP.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:MDP (4/10/2026, 7:00:00 PM)
3.94
+0.07 (+1.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)N/A N/A
Inst Owners1.21%
Inst Owner ChangeN/A
Ins Owners7.73%
Ins Owner ChangeN/A
Market Cap127.26M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.48 (89.85%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)6.47%
PT rev (3m)18.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.82 | ||
| P/S | 0.93 | ||
| P/FCF | 5.37 | ||
| P/OCF | 5.3 | ||
| P/B | 1.76 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.53 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.45
Fwd EY11.34%
FCF(TTM)0.73
FCFY18.64%
OCF(TTM)0.74
OCFY18.86%
SpS4.26
BVpS2.23
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROCE | 4.2% | ||
| ROIC | 3.02% | ||
| ROICexc | 3.61% | ||
| ROICexgc | 107.26% | ||
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% | ||
| FCFM | 17.26% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 2.1% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 1.57 | ||
| Cash Conversion | 127.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | 0.76 |
F-Score5
WACC8.77%
ROIC/WACC0.34
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.
What is the valuation status for MDP stock?
ChartMill assigns a valuation rating of 5 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
What is the profitability of MDP stock?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.
How financially healthy is MEDEXUS PHARMACEUTICALS INC?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.